July 21 (Reuters) - Resverlogix Corp RVX.TO :
* Results are expected in second half of 2016 from phase 1 study
* Resverlogix announces dosing of first two patients in expanded renal and orphan programs
Source text for Eikon: company coverage: RVX.TO